Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ATF4 | P18848 | 11/20 | 0.62 |
| ▸ | LMNA | P02545 | 2/20 | 0.55 |
| ▸ | MEN1 | O00255 | 1/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.47 |
| ▸ | GAA | P10253 | 1/20 | 0.47 |
| ▸ | NPC1 | O15118 | 1/20 | 0.46 |
| ▸ | TP53 | P04637 | 1/20 | 0.46 |
| ▸ | HPGD | P15428 | 1/20 | 0.46 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.46 |
| ▸ | RAB9A | P51151 | 1/20 | 0.46 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21618322 | 0.87 | ATF4 (0.83) | ATF4MEN1KMT2ANPC1RAB9A | |
| SCHEMBL21618326 | 0.86 | ATF4 (0.57) | ATF4HPGD | |
| SCHEMBL19569423 | 0.86 | ATF4 (0.86) | ATF4LMNANPC1TP53RAB9A | |
| SCHEMBL21618339 | 0.83 | ATF4 (0.69) | ATF4 | |
| SCHEMBL19569727 | 0.81 | ATF4 (0.65) | ATF4LMNA | |
| SCHEMBL21618341 | 0.81 | ATF4 (0.60) | ATF4GAA | |
| SCHEMBL19569780 | 0.80 | ATF4 (0.72) | ATF4 | |
| SCHEMBL21618352 | 0.79 | ATF4 (0.80) | ATF4MEN1KMT2ANPC1RAB9A | |
| SCHEMBL21618337 | 0.78 | ATF4 (0.53) | ATF4 | |
| SCHEMBL20974142 | 0.77 | ATF4 (1.00) | ATF4MEN1KMT2ANPC1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210253528-A1 | CHEMICAL COMPOUNDS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2021-08-19 | — | — | US | claimed |
| EP-3820843-A1 | CHEMICAL COMPOUNDS | GlaxoSmithKline Intellectual Property Development Limited (GB) | 2021-05-19 | — | — | EP | claimed |
| WO-2020012339-A1 | CHEMICAL COMPOUNDS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2020-01-16 | — | — | WO | claimed |
| US-20210253528-A1 | CHEMICAL COMPOUNDS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2021-08-19 | — | — | US | disclosed |
| EP-3820843-A1 | CHEMICAL COMPOUNDS | GlaxoSmithKline Intellectual Property Development Limited (GB) | 2021-05-19 | — | — | EP | disclosed |
| WO-2020012339-A1 | CHEMICAL COMPOUNDS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2020-01-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210253528-A1 | CHEMICAL COMPOUNDS | ATF4, EIF2AK4, ATF1 | ATF4 1/4885LMNA 1064/4885MEN1 3941/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.